Strategies and New Developments in the Management of Bacterial Meningitis

Miranda, Justine; Tunkel, Allan R.

doi:10.1016/j.idc.2009.06.014

Cited by 10 publications

(2 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Однако смертность от БГМ существенно не изменилась за последние 20 лет и находится в диапазоне от 15% до 25% в развитых странах и достигает 54-70% в странах с ограниченными ресурсами здравоохранения. У многих выживших пациентов сохраняются серьезные остаточные неврологические и психические расстройства, которые нередко служат причиной инвалидизации (5-40% случаев) [2][3][4][5][6].…”

Section: обзор литературыunclassified

Diagnosis and current treatment of pneumococcal meningitis

Агаркова¹,

Покровский²,

Корокина³

et al. 2019

CPT

View full text Add to dashboard Cite

Section: обзор литературыunclassified

Diagnosis and current treatment of pneumococcal meningitis

Агаркова¹,

Покровский²,

Корокина³

et al. 2019

CPT

View full text Add to dashboard Cite

“…Despite the effectiveness of the vaccination and treatment with antibiotics, negative outcomes are still associated with permanent neurological dysfunctions [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

Polymorphisms in DNA Repair Gene XRCC1 (Arg194Trp) and (Arg399Gln) and their Role in the susceptibility of Bacterial Meningitis

Pinheiro¹,

Fontes²,

Oliveira³

et al. 2015

J Meningitis

View full text Add to dashboard Cite

Meningitis is a contagious infectious disease with high rates of mortality. Most pathogenic microbes in humans have the ability to cause bacterial meningitis. However, the most common pathogens are Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae type b (Hib). It was found that the susceptibility to this infectious disease may be related to genetic characteristics of the host, such as the occurrence of single nucleotide polymorphisms (SNPs). In our previous work, association of SNPs in DNA repair genes with bacterial meningitis (BM) was demonstrated. In this study we evaluated two non-synonymous SNPs of the repair gene XRCC1 Arg194Trp (rs 1799782) and Arg399Gln (rs 25487) in patients with BM and health volunteers. The patient genotypes were investigated by PCR-RFLP. DNA damages were quantified using the genomic DNA with formamidopyrimidine DNA-glycosylase (FPG). Cytokines and chemokines were quantified from cerebrospinal fluid samples from BM patients. Concerning the SNP XRCC1 Arg194Trp, none association was found relation to BM. However, a higher frequency of heterozygous genotype for XRCC1 Arg399Gln was observed in the control group compared to the BM group (P = 0.043; OR = 0.426). DNA damage and cytokine/chemokines levels were not positively correlated with polymorphic genotypes. In conclusion, there is an indication that the SNP XRCC1 Arg399Gln could have a possible protective effect against BM.

show abstract

Treatment of Drug-resistant Pneumococcal Meningitis

Hameed

Tunkel

2010

Curr Infect Dis Rep

Self Cite

View full text Add to dashboard Cite

The approach to therapy in patients with pneumococcal meningitis has changed considerably over the past 20 years. Given the emergence of pneumococcal strains that are intermediately susceptible or highly resistant to penicillin, penicillin is not recommended as empiric therapy for presumed pneumococcal meningitis; the combination of vancomycin and a third-generation cephalosporin (either cefotaxime or ceftriaxone) should be used, pending isolation of the organism and in vitro susceptibility testing. For patients with pneumococcal meningitis caused by highly penicillin- or cephalosporin-resistant strains, the addition of rifampin can be considered if the organism is susceptible in vitro, the expected clinical or bacteriologic response is delayed, or the pneumococcal isolate has a cefotaxime or ceftriaxone minimal inhibitory concentration greater than 4 μg/mL. Meropenem is not a good option for monotherapy of highly penicillin- or cephalosporin-resistant strains, but use of a fluoroquinolone with in vitro activity against Streptococcus pneumoniae (specifically moxifloxacin) is an option in patients failing standard therapy; if used, however, it should be combined with a third-generation cephalosporin or vancomycin. Newer glycopeptides, daptomycin, and linezolid require further study to determine their efficacy in patients with pneumococcal meningitis.

show abstract

Strategies and New Developments in the Management of Bacterial Meningitis

Cited by 10 publications

References 103 publications

Diagnosis and current treatment of pneumococcal meningitis

Diagnosis and current treatment of pneumococcal meningitis

Polymorphisms in DNA Repair Gene XRCC1 (Arg194Trp) and (Arg399Gln) and their Role in the susceptibility of Bacterial Meningitis

Treatment of Drug-resistant Pneumococcal Meningitis

Contact Info

Product

Resources

About